Bradley Burget
Internal Medicine · Oklahoma City, OKNPI 1043531106
Payments from drug & device makers
Across 218 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$1K
- Pfizer$768
- Lilly USA, LLC$264
- Novo Nordisk$259
- AbbVie$220
- Boehringer Ingelheim$216
- plus $1K from 24 others
What the payments were for
- Travel & lodging$81720%
- Food & beverage$3,30080%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 11 | $1,307 |
| Pfizer | 66 | $768 |
| Lilly USA, LLC | 30 | $264 |
| Novo Nordisk | 19 | $259 |
| AbbVie | 12 | $220 |
| Boehringer Ingelheim | 13 | $216 |
| Merck | 12 | $188 |
| Amgen(2 entities) | 9 | $144 |
| GSK | 5 | $93 |
| AstraZeneca(2 entities) | 5 | $67 |
| Amarin Pharma, Inc. | 4 | $57 |
| Eisai Inc. | 2 | $46 |
| Sanofi-aventis U.S. LLC | 3 | $45 |
| Currax Pharmaceuticals LLC | 3 | $45 |
| Abbott | 3 | $41 |
| Sanofi Pasteur Inc. | 3 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Bayer | 2 | $31 |
| Astellas Pharma US Inc | 1 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $30 |
| Bristol Myers Squibb | 2 | $28 |
| Axsome Therapeutics, Inc. | 1 | $28 |
| Exact Sciences | 1 | $26 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Kaleo, Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $18 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Lundbeck LLC | 1 | $14 |
| IBSA Pharma Inc. | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $7 |
How this compares
$4,125 in reported general payments places this provider in the 85th percentile of 840 internal medicine providers in Oklahoma.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $18,857 |
| Gabapentin | 41 | $871 |
| Pantoprazole Sodium | 13 | $698 |
| Ezetimibe | 11 | $590 |
| Rosuvastatin Calcium | 18 | $557 |
| Atorvastatin Calcium | 20 | $368 |
| Losartan Potassium | 14 | $224 |
| Pioglitazone-MetforminPioglitazone Hcl/Metformin Hcl | 11 | $199 |
| Olmesartan Medoxomil | 15 | $188 |
| Pregabalin | 12 | $183 |
| Lisinopril | 12 | $167 |
| Amlodipine Besylate | 14 | $149 |
| Omeprazole | 12 | $135 |
| Levothyroxine Sodium | 19 | $132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $768 | $18,85718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 840 internal medicine providers in Oklahoma.
Other internal medicine in Oklahoma City
- Sagila GeorgeOklahoma City$1.8M
- Ryan MorganOklahoma City$775K
- Samid FarooquiOklahoma City$129K
- Minh PhanOklahoma City$77K
- Ali JafryOklahoma City$33K
- Stuart SchraderOklahoma City$29K
- Dale BratzlerOklahoma City$17K
- Karen ChopraOklahoma City$16K
- Charlsie RecordOklahoma City$14K
- Jeannette KelleyOklahoma City$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.